If you have been reading about reconstitution and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-03-15. Numbers and descriptions here follow the published literature rather than marketing material.
The peptide occurs naturally in thymic tissue and has been detected in serum and other biological fluids. Reported concentrations are low, and reliable measurement generally requires immunoassay or mass spectrometry with an enrichment step. It is released from a larger precursor, prothymosin alpha, by proteolytic cleavage, although the enzymes involved are not fully characterized. Whether circulating levels reflect thymic output specifically remains an open question.
Thymosin alpha 1 is a 28-amino-acid peptide first isolated from thymosin fraction 5, a bovine thymic extract. Its sequence begins with an acetylated serine residue and carries a high proportion of acidic residues, so the molecule has a net negative charge near neutral pH. Despite the shared name, it is unrelated in sequence to the thymosin beta family. Synthetic material prepared by solid-phase peptide synthesis is identical in sequence to the natural peptide.
Within the immune system, the peptide acts on several cell types rather than a single target. Reported activities include promotion of T-cell maturation, enhancement of natural killer cell activity, and modulation of cytokine production by dendritic cells and macrophages. Some of these effects appear to operate through toll-like receptor signaling, though the precise receptor-level mechanism remains debated. Whether the observed immune changes translate into clinical benefit is a separate question and depends on the indication studied.
The peptide was described in the 1970s as a component of thymic extracts, and early research focused on restoring immune function in immunodeficiency states. A synthetic version entered clinical development in the 1980s and is approved as a drug in several countries for conditions such as chronic hepatitis B and certain immunodeficiencies. Approval status varies widely by jurisdiction, and in the United States it is not an approved therapeutic. Regulatory and clinical positions differ, so statements about efficacy should be tied to specific indications and studies.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C129H215N33O55 | Calculated for the acetylated 28-residue peptide |
| Appearance | White to off-white powder | Lyophilized solid recovered from aqueous buffer |
| Solubility | Freely soluble in water | Typically dissolved in water or buffer before use |
| Typical storage | -20 C or below, desiccated | Protect from light and avoid repeated freeze-thaw cycles |
| Identity testing | Reverse-phase HPLC with mass spectrometry | Retention time and measured mass confirm the sequence |
Thymosin alpha-1 is supplied as a lyophilized powder in most research settings. The solid dissolves readily in water and in common aqueous buffers, and it is typically reconstituted shortly before use. Solutions are clear and colourless at ordinary working concentrations. Because the peptide is hygroscopic, weighing and reconstitution are usually performed with minimal exposure to ambient air. Aliquots are prepared to avoid repeated freeze-thaw cycles, and working solutions are kept cold.
Long-term storage is generally at minus twenty degrees Celsius or colder, preferably desiccated and protected from light. Lyophilized material is more stable than reconstituted solution, which degrades faster at room temperature. Stability depends on pH, ionic strength, and the presence of oxidising agents. Published stability data for the peptide are limited, so storage claims in catalogues should be treated as general guidance rather than measured guarantees. Freeze-thaw cycles are kept to a minimum.
The peptide was identified during work in the 1970s on thymosin fraction 5, a partially purified extract of calf thymus. Investigators separated that mixture and characterized individual components, one of which they named thymosin alpha-1. The same compound later received the international nonproprietary name thymalfasin. Commercial material is produced by solid-phase peptide synthesis rather than by extraction, so synthetic and natural forms share an identical sequence. Naming conventions vary across the literature, and readers should distinguish the alpha-1 peptide from other thymosins that have unrelated sequences and functions.
Thymosin beta-4 is a separate 43-residue peptide that binds actin and participates in cell migration; it shares no sequence similarity with thymosin alpha-1 despite the common family name. Other preparative materials, such as thymosin fraction 5 and thymopoietin, contain distinct mixtures or peptides. The shared thymosin label reflects the tissue of origin used in early purification, not a common structural core. Treating these molecules as interchangeable is a frequent source of confusion in laboratory reports and in popular summaries alike.
Thymosin alpha-1 is a synthetic peptide of 28 amino acid residues that corresponds to a naturally occurring fragment first isolated from thymus tissue. Its chain is acetylated at the amino terminus, a modification that shields the peptide from rapid cleavage by aminopeptidases. The molecule carries a net negative charge at physiological pH and dissolves freely in water. Researchers classify it as an immune-modulating agent rather than a classical hormone, because it acts on several cell types of both the innate and the adaptive immune system.
Lyophilized material is generally held at reduced temperature to slow degradation, and storage at minus twenty degrees Celsius or lower is common practice for long-term retention. Short-term working portions are often kept between two and eight degrees Celsius. Once dissolved, the peptide is less stable than the dry powder, and repeated freeze-thaw cycles are associated with loss of material and with aggregate formation. Vials are usually allowed to reach room temperature before opening so that condensation does not introduce moisture, and solutions are protected from light where practical.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography, which separates the peptide from closely related impurities and from truncated or oxidized variants. Mass spectrometry supplies the molecular mass and confirms the expected sequence length, while amino acid analysis can be used to check composition. Because the molecule has no chromophore beyond the peptide backbone, ultraviolet detection is typically performed at a low wavelength, where baseline interference from solvents and buffers is a practical concern. Water content and counter-ion content are often reported alongside purity.
Practical handling focuses on limiting adsorption and contamination. The peptide dissolves readily in water, and dilute solutions tend to adhere to plastic and glass surfaces, so an inert carrier protein or a defined buffer can reduce losses in laboratory work. Workers also record the counter-ion form, since an acetate or trifluoroacetate salt changes the mass balance of the weighed powder. Documentation of lot number, purity value, and storage history supports reproducibility when results from different laboratories are compared.
Lyophilized material is typically treated as a hygroscopic solid that should be brought to room temperature before the container is opened, which limits condensation on the powder. Reconstitution is commonly done with sterile water or a buffered diluent, and gentle mixing is preferred over vigorous agitation to reduce foaming and surface adsorption. Because peptides can bind to plastic and glass, diluents containing a small amount of carrier protein are sometimes used in laboratory work. Working solutions are generally aliquoted and prepared fresh rather than subjected to repeated freezing and thawing.
Stability depends on temperature, pH, and the number of freeze-thaw events the sample has experienced. Freeze-dried material is commonly held at -20 °C or colder, while reconstituted liquid is kept cold and used within a short window. Extreme pH and prolonged light exposure can promote deamidation, oxidation, or aggregation, particularly at asparagine and methionine positions. Adsorption to container walls can lower the measured concentration of a dilute solution even when the peptide molecules themselves remain intact.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, which separates the target peptide from truncated or chemically modified byproducts. Mass spectrometry confirms the expected molecular mass and can indicate acetylation state or sequence errors. Amino acid analysis and peptide mapping supply complementary sequence-level information, while endotoxin testing is relevant for preparations intended for cell or animal work. Purity figures reported by suppliers refer to the method used and are not directly comparable across laboratories unless conditions are stated.
== Further reading == Anie KA, Massaglia P (March 2014). "Psychological therapies for thalassaemia". The Cochrane Database of Systematic Reviews. 2014 (3) CD002890. doi:10.1002/14651858.cd002890.pub2. PMC 7138048. PMID 24604627. Galanello R, Cao A (February 2011). "Gene test review. Alpha-thalassemia". Genetics in Medicine. 13 (2): 83–8. doi:10.1097/GIM.0b013e3181fcb468. PMID 21381239. S2CID 209070781.
double-stranded RNA (dsRNA) Any RNA molecule that is composed of two antiparallel, complementary ribonucleotide polymers, known as strands, which are bonded together by hydrogen bonds between the complementary nucleobases. Though RNA usually occurs in single-stranded form, it is also capable of forming duplexes in the same way as DNA; an example is an mRNA transcript pairing with an antisense version of the same transcript, which effectively silences the gene from which the mRNA was transcribed by preventing translation. As in dsDNA, the base pairing in dsRNA usually causes the twin strands to coil around each other in the shape of a double helix.
=== Survival during freeze-drying processes === In 2017, a study was done to see the effects of six different substances on the growth and freeze- drying of Lactobacillus. Using Lactobacillus as starter cultures for the dairy industry depends on the number of viable and active cells. Currently, the preferred method to preserve the bacterial cells is through freeze-drying, however this also results in some strains being killed. This is due to various complications of freeze-drying, including the formation of ice crystals, loss of membrane fluidity, and the denaturation of important macromolecules. Regardless, freeze-drying has been used for decades in microbiological research as a way to store and stabilize cultures. Six substances, being sodium chloride, sorbitol, mannitol, mannose, monosodium glutamate, and betaine were tested to determine if they had any effect on the survivability of the cells after freeze-drying. Three of the six substances added had a positive effect on the growth and freeze-drying of Lactobacillus, being sodium chloride, sorbitol, and sodium glutamate. The results suggest that these substances have protective effects on Lactobacillus delbrueckii subsp. bulgaricus in small concentrations, but have little effect or even some harmful effects in higher concentrations. The optimal concentrations for sorbitol, sodium chloride and sodium glutamate for the desired protective effects were 0.15%, 0.6%, and 0.09% respectively. This was shown to increase cell viability drastically.
=== Two-step mechanism – autocatalysis model === In 1997, Finke and Watzky proposed a new kinetic model for the nucleation and growth of nanoparticles. This 2-step model suggested that constant slow nucleation (occurring far from supersaturation) is followed by autocatalytic growth where dispersity of nanoparticles is largely determined. This F-W (Finke-Watzky) 2-step model provides a firmer mechanistic basis for the design of nanoparticles with a focus on size, shape, and dispersity control. The model was later expanded to a 3-step and two 4-step models between 2004 and 2008. Here, an additional step was included to account for small particle aggregation, where two smaller particles could aggregate to form a larger particle. Next, a fourth step (another autocatalytic step) was added to account for a small particle agglomerating with a larger particle. Finally in 2014, an alternative fourth step was considered that accounted for a atomistic surface growth on a large particle.
Sources: en.wikipedia.org
== Uses == Viral load monitoring is used by HIV-positive people to develop a plan for their personal treatment of HIV/AIDS. A count of the viral load is routine before the start of HIV treatment. If the treatment is not changed, then viral load is monitored with testing every 3–4 months to confirm a stable low viral load. Patients who are medically stable and who have low viral load for two years may get viral load counts every 6 months instead of 3. If a viral load count is not stable or sufficiently low, then that might be a reason to modify the HIV treatment. If HIV treatment is changed, then the viral load should be tested 2–8 weeks later.
== Medical uses == Chlordiazepoxide hydrochloride is indicated for the short-term (2–4 weeks) treatment of anxiety that is severe and disabling or subjects a person to uncomfortable distress. It is also indicated as a treatment for the management of acute alcohol withdrawal syndrome. Chlordiazepoxide hydrochloride may be used by chronic benzodiazepine users to discontinue benzodiazepine use. The long half-life means that the patient’s final dose will last several days, making the likelihood of withdrawal symptoms lower. Tapering can last months to years. It is sometimes prescribed to ease symptoms of irritable bowel syndrome (IBS) when combined with clidinium bromide in the fixed dose medication, Librax.
Typical regimens included stimulants, such as amphetamines, as well as thyroid hormone, diuretics, digitalis, laxatives, and often a barbiturate to suppress the side effects of the stimulants. In 1967/1968 a number of deaths attributed to diet pills triggered a Senate investigation and the gradual implementation of greater restrictions on the market. While rainbow diet pills were banned in the US in the late 1960s, they reappeared in South America and Europe in the 1980s. In 1959, phentermine had been FDA approved and fenfluramine in 1973. In the early 1990s two studies found that a combination of the drugs was more effective than either on its own; fen-phen became popular in the United States and had more than 18 million prescriptions in 1996. Evidence mounted that the combination could cause valvular heart disease in up to 30 percent of those who had taken it, leading to withdrawal of fen-phen and dexfenfluramine from the market in September 1997. In the early 2020s, GLP-1 receptor agonists such as semaglutide (Ozempic, Wegovy) or tirzepatide (Zepbound) became popular for weight loss because they are more effective than earlier drugs, causing a shortage for patients prescribed these medications for type 2 diabetes, their original indication. After the FDA approved semaglutide and tirzepatide for chronic weight management, GLP-1 medications became available through various virtual weight loss programs. GLP-1 receptor agonists are associated with reduced risk of cardiovascular events (such as heart attack and stroke) in adults with obesity.
Sources: en.wikipedia.org
In the 1870s, the lack of a practical means of refrigerating peaches limited the markets available to Samuel Rumph, a Georgia peach grower. In 1875, he invented a refrigerated railcar and crates that allowed him to grow peaches on a very large scale and ship them to distant markets. He was the first to achieve this. His innovations created Georgia's fame for peaches, a crop now eclipsed economically by blueberries. Edwin Tobias Earl was born on a fruit ranch near Red Bluff, California, on May 30, 1858. His father was Joseph Earl, his mother Adelia Chaffee, and his brother was Guy Chaffee Earl. He started his career in fruit shipping. By 1886, he was President of the Earl Fruit Company. In 1890, he invented the refrigerator car to transport fruits to the East Coast of the United States. He established the Continental Fruit Express and invested US$2,000,000 in refrigerator cars. In 1901, he sold his refrigerator cars to Armour and Company of Chicago and became a millionaire. By the turn of the 20th century, manufactured ice became more common. The Pacific Fruit Express (PFE) - a joint venture between the Union Pacific and Southern Pacific railroads, with a fleet of 6,600 refrigerator cars built by the American Car and Foundry Company (ACF) - maintained seven natural harvesting facilities, and operated 18 artificial ice plants. Their largest plant (located in Roseville, California) produced 1,200 short tons (1,100 t) of ice daily, and Roseville's docks could accommodate up to 254 cars.
=== Graphene ligand/complex === Graphene can be a ligand to coordinate metals and metal ions by introducing functional groups. Structures of graphene ligands are similar to e.g. metal-porphyrin complex, metal-phthalocyanine complex, and metal-phenanthroline complex. Copper and nickel ions can be coordinated with graphene ligands.
== As polyelectrolytes == Because many substituted derivatives are known, cyclopropenium salts have attracted attention as possible polyelectrolytes, relevant to technologies such as desalination and fuel cells. The tris(dialkylamino)cyclopropenium salts have been particularly evaluated because of their high stability.
In 1981, Frank D. Hickingbotham (b. 1936) opened the first TCBY in Little Rock, Arkansas. TCBY began franchising the following year, and had expanded to over 100 locations by 1984. Prior to 1984, the company's name was "This Can't Be Yogurt," but a lawsuit from a competitor, I Can't Believe It's Yogurt!, forced TCBY to create a new name from its initials, eventually using "The Country's Best Yogurt". TCBY began co-branding with Taco Bell, McDonald's, Subway, and Burger King in 1995. In 1991 TCBY moved into the tallest building in Arkansas, the forty-story Simmons Tower located in downtown Little Rock, and the building was renamed The TCBY Tower until 2000 when TCBY vacated. Mrs. Fields acquired TCBY in early 2000 and became Mrs. Fields Famous Brands. The combined company relocated headquarters to Broomfield, Colorado in 2012. TCBY was also present in Honduras, Costa Rica and Nicaragua for several years, but closed all of its branches. In 2001, there were 1,777 TCBY locations across the United States. By 2011, after several waves of closings, there were 405.
Sources: en.wikipedia.org
It is a 28-amino-acid peptide originally purified from a bovine thymic extract and later produced synthetically. It is studied mainly for its effects on immune cell function.
No. The two peptides share part of a name but differ in length, sequence, and net charge. Literature searches that treat them as one compound return misleading results.
Solid-phase peptide synthesis is the usual route, and recombinant expression has also been described. Both approaches produce material matching the natural sequence.
It corresponds to a fragment of the larger protein prothymosin alpha, which is present in many tissues. The isolated 28-amino-acid peptide was originally obtained from thymus preparations, and the pharmaceutical product is synthesized rather than extracted. The term therefore describes both a natural fragment and a manufactured drug substance.